Buy Marksans Pharma@101.65.
This is one of those mid-sized pharma companies, where if you actually look at it in terms of stock price, then they have done phenomenally well because most of the company's business comes from regulated overseas markets such as UK and Australia. The company has subsidiaries through which it is been able to sell a mixture of OTC and generic products. But what really sets the company apart is its softgel capsule business.
There is less competition in this segment and the price erosion as compared with the other generic spaces is low. Among the new findings that Marksans has, a bulk of them is within the SGC space. So, that is the strategy that will incrementally help) the company them in the time to come
This is one of those mid-sized pharma companies, where if you actually look at it in terms of stock price, then they have done phenomenally well because most of the company's business comes from regulated overseas markets such as UK and Australia. The company has subsidiaries through which it is been able to sell a mixture of OTC and generic products. But what really sets the company apart is its softgel capsule business.
There is less competition in this segment and the price erosion as compared with the other generic spaces is low. Among the new findings that Marksans has, a bulk of them is within the SGC space. So, that is the strategy that will incrementally help) the company them in the time to come
A couple of two-three months back the company acquired a US-based company that deal in any case is cash accretive and EPS accretive. Going forward, thwill provide a front end for their US operations. The US SGC market is actually also one of the key positives for the company. The company's Goa facility is USFDA approved. So, a lot of positives are really for a company of its size. We expect Marksans to really report stronger earnings as quarters go by.
So fundamentally its a buy for a target of 150+ in next 1 year.
